Mckinley Capital Management LLC Argenx Se Transaction History

Mckinley Capital Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$369.35 - $548.43 $1.82 Million - $2.7 Million	-4,930 Reduced 82.17%	1,070 $526,000
Q1 2023 May 11, 2023	SELL	$334.23 - $403.65 $5.08 Million - $6.14 Million	-15,200 Reduced 71.7%	6,000 $2.24 Million
Q4 2022 Jan 18, 2023	SELL	$342.17 - $402.31 $1.11 Million - $1.3 Million	-3,240 Reduced 13.26%	21,200 $0
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $8.39 Million - $9.67 Million	24,440 New	24,440 $8.63 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Mckinley Capital Management LLC , based on Form 13F filings with the SEC.

Stay updated on Mckinley Capital Management LLC with notifications on news.